Does Rallies show Form 4 insider transactions for TRIB?

Yes. Rallies tracks TRIB insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is TRIB research on Rallies investment advice?

No. Rallies provides research, data, and educational context for TRIB. It does not provide personalized investment advice.

TRIB (Trinity Biotech plc) Stock Analysis - Insider Trades

Trinity Biotech plc (TRIB) is a publicly traded Healthcare sector company. As of May 21, 2026, TRIB trades at $0.59 with a market cap of $11.54M and a P/E ratio of 0.00. TRIB moved +6.65% today. Year to date, TRIB is -20.85%; over the trailing twelve months it is -25.11%. Its 52-week range spans $0.48 to $3.44. Rallies surfaces TRIB's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading TRIB stock inside the company?

Recent TRIB insider activity includes ROBERT R MCCORMICK TRIBUNE FOUNDATION sold 17.80K, ROBERT R MCCORMICK TRIBUNE FOUNDATION sold 92.00K, and ROBERT R MCCORMICK TRIBUNE FOUNDATION sold 65.20K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

TRIB Key Metrics

Key financial metrics for TRIB
Metric	Value
Price	$0.59
Market Cap	$11.54M
P/E Ratio	0.00
EPS	$0.00
Dividend Yield	0.22%
52-Week High	$3.44
52-Week Low	$0.48
Volume	170
Avg Volume	0
Revenue (TTM)	$0
Net Income	$0
Gross Margin	0.00%

Recent TRIB Insider Trades

ROBERT R MCCORMICK TRIBUNE FOUNDATION sold 17.80K (~$924.52K) on Feb 18, 2004.
ROBERT R MCCORMICK TRIBUNE FOUNDATION sold 92.00K (~$4.82M) on Feb 17, 2004.
ROBERT R MCCORMICK TRIBUNE FOUNDATION sold 65.20K (~$3.39M) on Feb 13, 2004.

Latest TRIB News

Trinity Biotech’s Enhanced EpiCapture Test Achieves 85% AUC in 750-Sample Study — Mar 23, 2026
Trinity Biotech to Commercialize Sjögren’s Syndrome Biomarkers via NYSDOH-Approved Lab — Mar 18, 2026
Trinity Biotech Begins Brazil Launch of IFCC Gold Premier Hb9210 System — Mar 12, 2026
Trinity Biotech Reports $11.5–12.5M Q4 Revenue, CGM+ MARD Improvement — Mar 10, 2026
Trinity Biotech Secures $25M Standby Equity Line at 3% VWAP Discount — Feb 25, 2026

TRIB Analyst Consensus

TRIB analyst coverage data. Average price target: $0.00.

Common questions about TRIB

Who is trading TRIB stock inside the company?: Recent TRIB insider activity includes ROBERT R MCCORMICK TRIBUNE FOUNDATION sold 17.80K, ROBERT R MCCORMICK TRIBUNE FOUNDATION sold 92.00K, and ROBERT R MCCORMICK TRIBUNE FOUNDATION sold 65.20K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for TRIB?: Yes. Rallies tracks TRIB insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is TRIB research on Rallies investment advice?: No. Rallies provides research, data, and educational context for TRIB. It does not provide personalized investment advice.